BRWA
MRVI icon

B. Riley Wealth Advisors’s Maravai LifeSciences MRVI Stock Holding History

B. Riley Wealth Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,111
Closed -$214K – 1443
2021
Q2 		$214K Buy
+5,111
New +$198K 0.01% 1187

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

B. Riley Wealth Advisors's MRVI Position: Q3 2021 in Review

B. Riley Wealth Advisors sold out of Maravai LifeSciences (MRVI) in Q3 2021, closing a stake of 5,111 shares — an estimated $214K sold.

B. Riley Wealth Advisors first reported a position in MRVI in Q2 2021 and held it in 1 quarter. The position peaked at $214K in Q2 2021. 228 funds tracked by Wall St. Rank hold MRVI as of Q3 2021.

  • B. Riley Wealth Advisors reported no remaining Maravai LifeSciences position as of Q3 2021 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 5,111 Maravai LifeSciences shares in Q3 2021, an estimated $214K.
  • B. Riley Wealth Advisors first reported a position in Maravai LifeSciences in Q2 2021 and held it in 1 quarter.
  • B. Riley Wealth Advisors's Maravai LifeSciences position peaked at $214K in Q2 2021.
  • 228 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2021.

Based on B. Riley Wealth Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.